{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:31:48Z","timestamp":1793140308287,"version":"4.5.0"},"reference-count":46,"publisher":"American Chemical Society (ACS)","issue":"23","license":[{"start":{"date-parts":[[2017,11,4]],"date-time":"2017-11-04T00:00:00Z","timestamp":1509753600000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_termsofuse.html"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite the availability of numerous antiepileptic drugs, 20\u201330% of epileptic patients are pharmacoresistant with seizures not appropriately controlled. Consequently, new strategies to address this unmet medical need are required. T-type calcium channels play a key role in neuronal excitability and burst firing, and selective triple T-type calcium channel blockers could offer a new way to treat various CNS disorders, in particular epilepsy. Herein we describe the identification of new 1,4-benzodiazepines as brain penetrant and selective triple T-type calcium channel blockers. From racemic hit 4, optimization work led to the preparation of pyridodiazepine 31c with improved physicochemical properties, solubility, and metabolic stability. The racemic mixture was separated by chiral preparative HPLC, and the resulting lead compound (3\u00a0R\u00a0,5\u00a0S\u00a0)-31c showed promising efficacy in the WAG\/Rij-rat model of generalized nonconvulsive absence-like epilepsy.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6b01356","type":"journal-article","created":{"date-parts":[[2016,11,4]],"date-time":"2016-11-04T17:11:16Z","timestamp":1478279476000},"page":"10661-10675","source":"Crossref","is-referenced-by-count":32,"title":["Structure\u2013Activity\nRelationship, Drug Metabolism\nand Pharmacokinetics Properties Optimization, and\n                    <i>in Vivo<\/i>\n                    Studies of New Brain Penetrant Triple T-Type Calcium Channel\nBlockers"],"prefix":"10.1021","volume":"59","author":[{"given":"Romain","family":"Siegrist","sequence":"first","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Pozzi","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gae\u0308l","family":"Jacob","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Torrisi","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kilian","family":"Colas","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Braibant","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Mawet","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Pfeifer","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"de Kanter","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Roch","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kessler","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Corminboeuf","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2409-2176","authenticated-orcid":true,"given":"Olivier","family":"Bezenc\u0327on","sequence":"additional","affiliation":[{"name":"Actelion Pharmaceuticals Ltd. , , Gewerbestrasse 16 , ,","place":["Allschwil, Switzerland, CH-4123"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2016,11,4]]},"reference":[{"key":"2026090314003710000_cit1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1093\/brain\/awh682","article-title":"Molecular\nand cellular mechanisms of pharmacoresistance in epilepsy","volume":"129","author":"Remy","year":"2006","journal-title":"Brain"},{"key":"2026090314003710000_cit2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.phrs.2015.11.007","article-title":"Challenges in the clinical development\nof new antiepileptic drugs","volume":"103","author":"Franco","year":"2016","journal-title":"Pharmacol. Res."},{"key":"2026090314003710000_cit3a","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrd4126","article-title":"New avenues\nfor anti-epileptic drug discovery and development","volume":"12","author":"Loscher","year":"2013","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"Suppl\n4","key":"2026090314003710000_cit3b","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/epi.12294","article-title":"Development of new treatment approaches\nfor epilepsy: unmet needs and opportunities","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"2026090314003710000_cit4","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1152\/physrev.00018.2002","article-title":"Molecular\nphysiology of low-voltage-activated t-type calcium channels","volume":"83","author":"Perez-Reyes","year":"2003","journal-title":"Physiol. Rev."},{"key":"2026090314003710000_cit5","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1523\/JNEUROSCI.19-06-01895.1999","article-title":"Differential distribution of three\nmembers of a gene\nfamily encoding low voltage-activated (T-type) calcium channels","volume":"19","author":"Talley","year":"1999","journal-title":"J. Neurosci."},{"key":"2026090314003710000_cit6","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1152\/physrev.00010.2012","article-title":"T-type Ca2+ channels in normal and abnormal\nbrain functions","volume":"93","author":"Cheong","year":"2013","journal-title":"Physiol. Rev."},{"key":"2026090314003710000_cit7","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00424-013-1353-6","article-title":"The many faces of T-type\ncalcium channels","volume":"466","author":"Lambert","year":"2014","journal-title":"Pfluegers Arch."},{"key":"2026090314003710000_cit8","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.coph.2007.12.003","article-title":"T-type\nCa2+ channels as therapeutic targets in the nervous system","volume":"8","author":"Shin","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"2026090314003710000_cit9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s00424-014-1466-6","article-title":"The T-type\ncalcium\nchannel as a new therapeutic target for Parkinson\u2019s disease","volume":"466","author":"Yang","year":"2014","journal-title":"Pfluegers Arch."},{"key":"2026090314003710000_cit10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00424-014-1484-4","article-title":"T-type calcium channels in chronic\npain: mouse models\nand specific blockers","volume":"466","author":"Francois","year":"2014","journal-title":"Pfluegers Arch."},{"key":"2026090314003710000_cit11","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.bcp.2012.12.017","article-title":"Inhibition\nof T-type calcium channels disrupts Akt signaling and promotes apoptosis\nin glioblastoma cells","volume":"85","author":"Valerie","year":"2013","journal-title":"Biochem. Pharmacol."},{"key":"2026090314003710000_cit12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1021\/ml100170e","article-title":"Short-acting\nT-type calcium channel antagonists significantly modify sleep architecture\nin rodents","volume":"1","author":"Yang","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"key":"2026090314003710000_cit13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/bcp.12205","article-title":"Low threshold\nT-type calcium channels as targets for novel epilepsy treatments","volume":"77","author":"Powell","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2026090314003710000_cit14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00424-009-0772-x","article-title":"Role of voltage-gated calcium channels\nin epilepsy","volume":"460","author":"Zamponi","year":"2010","journal-title":"Pfluegers Arch."},{"key":"2026090314003710000_cit15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s00424-014-1461-y","article-title":"T-type Ca2+ channels in absence epilepsy","volume":"466","author":"Cheong","year":"2014","journal-title":"Pfluegers Arch."},{"key":"2026090314003710000_cit16","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00424-014-1454-x","article-title":"T-type calcium\nchannel blockers as\nneuroprotective agents","volume":"466","author":"Kopecky","year":"2014","journal-title":"Pfluegers Arch."},{"key":"2026090314003710000_cit17","doi-asserted-by":"publisher","first-page":"6471","DOI":"10.1021\/jm800830n","article-title":"Discovery\nof 1,4-substituted piperidines as potent and selective inhibitors\nof T-type calcium channels","volume":"51","author":"Yang","year":"2008","journal-title":"J. Med. Chem."},{"key":"2026090314003710000_cit18","doi-asserted-by":"publisher","first-page":"121ra19","DOI":"10.1126\/scitranslmed.3003120","article-title":"T-type calcium channel\nblockers that attenuate thalamic burst firing and suppress absence\nseizures","volume":"4","author":"Tringham","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"2026090314003710000_cit19","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1523\/JNEUROSCI.2081-08.2009","article-title":"Genetic\nenhancement of thalamocortical network activity by elevating alpha\n1g-mediated low-voltage-activated calcium current induces pure absence\nepilepsy","volume":"29","author":"Ernst","year":"2009","journal-title":"J. Neurosci."},{"key":"2026090314003710000_cit20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0896-6273(01)00343-9","article-title":"Lack of\nthe burst\nfiring of thalamocortical relay neurons and resistance to absence\nseizures in mice lacking alpha(1G) T-type Ca(2+) channels","volume":"31","author":"Kim","year":"2001","journal-title":"Neuron"},{"key":"2026090314003710000_cit21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1113\/jphysiol.2013.264176","article-title":"Mechanisms\nby which a CACNA1H mutation\nin epilepsy patients increases seizure susceptibility","volume":"592","author":"Eckle","year":"2014","journal-title":"J. Physiol."},{"key":"2026090314003710000_cit22","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1021\/jm800419w","article-title":"Design, synthesis,\nand evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type\nCa2+ channel antagonist","volume":"51","author":"Shipe","year":"2008","journal-title":"J. Med.\nChem."},{"key":"2026090314003710000_cit23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1517\/13543776.2011.536532","article-title":"T-type calcium channels inhibitors:\na patent review","volume":"21","author":"Giordanetto","year":"2011","journal-title":"Expert Opin. Ther. Pat."},{"key":"2026090314003710000_cit24","doi-asserted-by":"publisher","first-page":"8398","DOI":"10.1021\/acs.jmedchem.6b00756","article-title":"Preparation, antiepileptic activity\nand cardiovascular safety of\ndihydropyrazoles as brain-penetrant T-type calcium channel blockers","volume":"59","author":"Remen","year":"2016","journal-title":"J. Med. Chem."},{"key":"2026090314003710000_cit25a","unstructured":"(a)\n          \n            \n              Barrow, J. C.; Bieber, K.-A. S.; Cube, R. V.; Mattern, M. C.; Reger, T. S.; Shu, Y.; Yang, Z.-Q.\n          Pyridyl amide T-Type calcium channel antagonists. WO2007120729 A2, April 12, 2007."},{"key":"2026090314003710000_cit25b","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1016\/j.bmcl.2011.01.089","article-title":"Pyridyl\namides as potent inhibitors of T-type calcium channels","volume":"21","author":"Reger","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026090314003710000_cit26","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/hup.2289","article-title":"Randomized\ncontrolled study of the\nT-type calcium channel antagonist MK-8998 for the treatment of acute\npsychosis in patients with schizophrenia","volume":"28","author":"Egan","year":"2013","journal-title":"Hum.\nPsychopharmacol."},{"key":"2026090314003710000_cit27","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.neuropharm.2015.09.032","article-title":"Blockade of T-type calcium channels prevents tonic-clonic seizures\nin a maximal electroshock seizure model","volume":"101","author":"Sakkaki","year":"2016","journal-title":"Neuropharmacology"},{"key":"2026090314003710000_cit28","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/acsmedchemlett.5b00023","article-title":"Optimization of\nADME properties for sulfonamides leading to the discovery of a T-type\ncalcium channel blocker, ABT-639","volume":"6","author":"Zhang","year":"2015","journal-title":"ACS Med. Chem.\nLett."},{"key":"2026090314003710000_cit29","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1517\/17460441.2013.796926","article-title":"The design\nand discovery of T-type calcium channel inhibitors for the treatment\nof central nervous system disorders","volume":"8","author":"Choi","year":"2013","journal-title":"Expert\nOpin. Drug Discovery"},{"key":"2026090314003710000_cit30","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1089\/adt.2006.054","article-title":"Validation of high throughput screening\nassays against\nthree subtypes of Ca(v)3 T-type channels using molecular and pharmacologic\napproaches","volume":"5","author":"Xie","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"2026090314003710000_cit31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1021\/co500025f","article-title":"Bis(2,2,2-trifluoroethyl)\ncarbonate as a condensing agent in one-pot parallel synthesis of unsymmetrical\naliphatic ureas","volume":"16","author":"Bogolubsky","year":"2014","journal-title":"ACS Comb. Sci."},{"key":"2026090314003710000_cit33","doi-asserted-by":"publisher","first-page":"14314","DOI":"10.1021\/ja5093612","article-title":"Direct catalytic N-alkylation\nof\namines with carboxylic acids","volume":"136","author":"Sorribes","year":"2014","journal-title":"J. Am. Chem. Soc."},{"key":"2026090314003710000_cit34","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1002\/jlcr.2580340910","article-title":"A convenient\nmethod for the cyanation of aromatic iodo compounds","volume":"34","author":"Carr","year":"1994","journal-title":"J. Labelled Compd. Radiopharm."},{"key":"2026090314003710000_cit35","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/cber.19190520840","article-title":"Das am Ringkohlenstoff\ngebundene Halogen und sein Ersatz\ndurch andere Substituenten. I. Mitteilung: Ersatz des Halogens durch\ndie Carboxylgruppe","volume":"52","author":"Rosenmund","year":"1919","journal-title":"Ber. Dtsch. Chem. Ges. B"},{"key":"2026090314003710000_cit36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jlac.19314880107","article-title":"Fluoranthen und seine Derivate","volume":"488","author":"von Braun","year":"1931","journal-title":"Liebigs Ann. Chem."},{"key":"2026090314003710000_cit37","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1039\/p19900001127","article-title":"Influence of substrate\nstructure\non copper(I)-assisted cyanide substitution in aryl halides","volume":"1","author":"Connor","year":"1990","journal-title":"J. Chem. Soc., Perkin Trans. 1"},{"key":"2026090314003710000_cit38","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/BF01518076","article-title":"Untersuchungen\nu\u0308ber Perylen und seine Derivate","volume":"48","author":"Pongratz","year":"1927","journal-title":"Monatsh.\nChem."},{"key":"2026090314003710000_cit39","unstructured":"Wang, Z. X.; Li, Y.; Guntoori, B.\n          Novel process for the preparation\nof flecainide, its pharmaceutically acceptable salts and important\nintermediates thereof. US20050059825 A1, March\n17, 2005."},{"key":"2026090314003710000_cit40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1039\/b400878b","article-title":"Synthesis of aryl azides\nand vinyl azides via proline-promoted\nCuI-catalyzed coupling reactions","author":"Zhu","year":"2004","journal-title":"Chem. Commun."},{"key":"2026090314003710000_cit41","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1021\/jo047758b","article-title":"Synthesis of aryl sulfones\nvia L-proline-promoted CuI-catalyzed coupling\nreaction of aryl halides with sulfinic acid salts","volume":"70","author":"Zhu","year":"2005","journal-title":"J. Org. Chem."},{"key":"2026090314003710000_cit42","unstructured":"Huang, Z.; Jin, J.; Machajewski, T. D.; Antonios-Mccrea, W. R.; Mckenna, M.; Poon, D.; Renhowe, P. A.; Sendzik, M.; Shafer, C. M.; Smith, A.\n          Novel heterocyclic compounds and uses therof. WO2009115572\nA2, September 24, 2009."},{"key":"2026090314003710000_cit43","unstructured":"Zsebo, K. M.; Dahl, R.\n          Methods for treating\ndiseases associated with the modulation of serca. WO2010088450 A2, August 5, 2010."},{"key":"2026090314003710000_cit44","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/B978-0-12-386009-5.00003-5","article-title":"Deuterium in drug discovery and development","volume":"46","author":"Harbeson","year":"2011","journal-title":"Annu. Rep. Med. Chem."},{"key":"2026090314003710000_cit45","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1023\/A:1026179013847","article-title":"Genetic\nanimal models for absence epilepsy: a review\nof the WAG\/Rij strain of rats","volume":"33","author":"Coenen","year":"2003","journal-title":"Behav. Genet."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6b01356","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/59\/23\/10661\/67315081\/acs.jmedchem.6b01356.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/59\/23\/10661\/67315081\/acs.jmedchem.6b01356.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T08:11:25Z","timestamp":1788855085000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/59\/23\/10661\/1304774\/Structure-Activity-Relationship-Drug-Metabolism"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,4]]},"references-count":46,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2016,11,4]]},"published-print":{"date-parts":[[2016,12,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6b01356","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,4]]}}}